PL4249073T3 - Pirymidyny do degradacji kinazy tyrozynowej Brutona - Google Patents

Pirymidyny do degradacji kinazy tyrozynowej Brutona

Info

Publication number
PL4249073T3
PL4249073T3 PL23162731.6T PL23162731T PL4249073T3 PL 4249073 T3 PL4249073 T3 PL 4249073T3 PL 23162731 T PL23162731 T PL 23162731T PL 4249073 T3 PL4249073 T3 PL 4249073T3
Authority
PL
Poland
Prior art keywords
bruton
pyrimidines
degrading
tyrosine kinase
tyrosine
Prior art date
Application number
PL23162731.6T
Other languages
English (en)
Inventor
Zhiguo BIAN
Jason Burke
Zhaozhong Jia
Xingyu Jiang
Matthew Katcher
Venkat Reddy Mali
Violeta Marin
Elizabeth Noey
Akinori Okano
Alexey Rivkin
Spencer Scholz
Kevin Woller
Xianrui Zhao
Ashley ADAMS
Berenger BIANNIC
Shahab MORTEZAEI
Joshua Payette
Jeffery Zablocki
Original Assignee
Abbvie Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Inc. filed Critical Abbvie Inc.
Publication of PL4249073T3 publication Critical patent/PL4249073T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PL23162731.6T 2022-03-22 2023-03-17 Pirymidyny do degradacji kinazy tyrozynowej Brutona PL4249073T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202263322505P 2022-03-22 2022-03-22

Publications (1)

Publication Number Publication Date
PL4249073T3 true PL4249073T3 (pl) 2025-03-17

Family

ID=85776045

Family Applications (1)

Application Number Title Priority Date Filing Date
PL23162731.6T PL4249073T3 (pl) 2022-03-22 2023-03-17 Pirymidyny do degradacji kinazy tyrozynowej Brutona

Country Status (23)

Country Link
US (2) US12172992B2 (pl)
EP (2) EP4249073B1 (pl)
JP (2) JP7805983B2 (pl)
KR (1) KR20240163634A (pl)
CN (1) CN119072475A (pl)
AR (1) AR128842A1 (pl)
AU (1) AU2023237882A1 (pl)
CO (1) CO2024012427A2 (pl)
DK (1) DK4249073T3 (pl)
ES (1) ES3014292T3 (pl)
FI (1) FI4249073T3 (pl)
HR (1) HRP20241722T1 (pl)
HU (1) HUE070665T2 (pl)
IL (1) IL314260A (pl)
LT (1) LT4249073T (pl)
MX (1) MX2024011120A (pl)
PL (1) PL4249073T3 (pl)
PT (1) PT4249073T (pl)
RS (1) RS66349B1 (pl)
SI (1) SI4249073T1 (pl)
TW (1) TW202346287A (pl)
WO (1) WO2023183811A1 (pl)
ZA (1) ZA202504401B (pl)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3240051A1 (en) * 2021-12-30 2023-07-06 Beigene Switzerland Gmbh Degradation of bruton's tyrosine kinase (btk) by conjugation of btk inhibitors with e3 ligase ligand and methods of use
US20260028345A1 (en) 2024-07-26 2026-01-29 Ascentage Pharma (Suzhou) Co., Ltd. Btk degrader and use thereof
WO2026021570A1 (en) * 2024-07-26 2026-01-29 Ascentage Pharma (Suzhou) Co., Ltd. Btk degrader and use thereof

Family Cites Families (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ244394A3 (en) 1993-10-08 1995-06-14 Shell Int Research Herbicidal 1,2,4-oxadiazolecarboxylic acids amides, esters or halides
JP3402153B2 (ja) 1997-10-01 2003-04-28 凸版印刷株式会社 耐水性および剛性に優れた含浸紙
US6998233B2 (en) 1998-06-26 2006-02-14 Sunesis Pharmaceuticals, Inc. Methods for ligand discovery
US7214487B2 (en) 1998-06-26 2007-05-08 Sunesis Pharmaceuticals, Inc. Methods for identifying compounds that modulate enzymatic activities by employing covalently bonded target-extender complexes with ligand candidates
AU2573102A (en) 2000-11-21 2002-06-03 Sunesis Pharmaceuticals Inc An extended tethering approach for rapid identification of ligands
US20080220441A1 (en) 2001-05-16 2008-09-11 Birnbaum Eva R Advanced drug development and manufacturing
US9157875B2 (en) 2001-05-16 2015-10-13 Benjamin P. Warner Drug development and manufacturing
CN101252991B (zh) 2005-06-28 2012-10-03 住友化学株式会社 过氧化物分解催化剂
EP2084519B1 (en) 2006-10-10 2012-08-01 Los Alamos National Security, LLC X-ray fluorescence analysis method
WO2010072228A1 (en) 2008-12-22 2010-07-01 Xigen S.A. Novel transporter constructs and transporter cargo conjugate molecules
AR078793A1 (es) 2009-10-27 2011-12-07 Orion Corp Derivados de carboxamidas no esteroidales y acil hidrazona moduladores de receptores androgenicos de tejido selectivo (sarm), composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del cancer de prostata entre otros
PH12013500301A1 (en) 2010-08-16 2013-03-25 Boehringer Ingelheim Int Oxadiazole inhibitors of leukotriene production
WO2012027322A1 (en) 2010-08-26 2012-03-01 Boehringer Ingelheim International Gmbh Oxadiazole inhibitors of leukotriene production
KR101615420B1 (ko) 2010-12-16 2016-04-26 제넨테크, 인크. Th2 억제에 관한 진단 및 치료
TWI573792B (zh) 2012-02-01 2017-03-11 歐陸斯迪公司 新穎治療劑
AR089853A1 (es) 2012-02-01 2014-09-24 Boehringer Ingelheim Int Inhibidores de oxadiazol de la produccion de leucotrienos para terapia de combinacion, composicion farmaceutica, uso
CN104662018B (zh) 2012-04-20 2017-10-24 阿迪维纳斯治疗有限公司 取代的杂双环化合物、组合物及其医疗应用
BR112015007513A2 (pt) 2012-10-26 2017-07-04 Hoffmann La Roche inibidores de tirosina quinase de bruton
PL3099717T3 (pl) 2014-01-31 2019-10-31 Novartis Ag Cząsteczki przeciwciała dla TIM-3 i ich zastosowanie
EA201691765A1 (ru) 2014-03-14 2016-12-30 Новартис Аг Молекулы антител против lag-3 и их применения
KR102359214B1 (ko) 2014-04-04 2022-02-07 델 마 파마슈티컬스 폐의 비소세포 암종 및 난소암을 치료하기 위한 디안하이드로갈락티톨 및 이의 유사체 또는 유도체
KR101582834B1 (ko) 2014-04-14 2016-01-08 한국세라믹기술원 비수계 그래핀 코팅액 제조 방법
KR101635848B1 (ko) 2014-04-14 2016-07-05 한국세라믹기술원 탄소 비결합성 금속 나노입자가 함유된 잉크 기제 제조 방법 및 금속 나노입자가 분산된 잉크
CN107001362A (zh) 2014-10-06 2017-08-01 默克专利有限公司 用作btk抑制剂的杂芳基化合物及其用途
US9694084B2 (en) 2014-12-23 2017-07-04 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
GB201506871D0 (en) 2015-04-22 2015-06-03 Glaxosmithkline Ip Dev Ltd Novel compounds
CA2988436A1 (en) 2015-07-13 2017-01-19 Arvinas, Inc. Alanine-based modulators of proteolysis and associated methods of use
CN109152843A (zh) 2016-05-20 2019-01-04 豪夫迈·罗氏有限公司 Protac抗体缀合物及其使用方法
GB201610147D0 (en) 2016-06-10 2016-07-27 Glaxosmithkline Ip Dev Ltd Novel compounds
AU2017312970B2 (en) 2016-08-16 2021-08-12 Merck Patent Gmbh 2-oxo-imidazopyridines as reversible BTK inhibitors and uses thereof
GB201614134D0 (en) 2016-08-18 2016-10-05 Glaxosmithkline Ip Dev Ltd Novel compounds
CA3042294A1 (en) 2016-11-22 2018-05-31 Dana-Farber Cancer Institute, Inc. Degradation of bruton's tyrosine kinase (btk) by conjugation of btk inhibitors with e3 ligase ligand and methods of use
US10842878B2 (en) 2016-11-22 2020-11-24 Dana-Farber Cancer Institute, Inc. Degradation of Bruton's tyrosine kinase (BTK) by conjugation of BTK inhibitors with E3 ligase ligand and methods of use
UY37559A (es) 2017-01-06 2018-05-31 Pharmacyclics Llc Pirazolo[3,4-b]piridina y pirrolo[2,3-b]piridina como inhibidores de la tirosina quinasa de bruton
WO2018137644A1 (zh) 2017-01-24 2018-08-02 南京明德新药研发股份有限公司 Lsd1抑制剂及其制备方法和应用
RS65386B1 (sr) 2017-04-14 2024-04-30 Biogen Ma Inc Benzoazepinski analozi kao sredstva za inhibiciju brutonove tirozin kinaze
EP3645001B1 (en) 2017-06-29 2024-07-03 G1 Therapeutics, Inc. Morphic forms of git38 and methods of manufacture thereof
CN109422752B (zh) 2017-09-03 2023-04-07 上海美志医药科技有限公司 一类具有抑制并降解布鲁顿酪氨酸蛋白激酶Btk活性的化合物
WO2019084030A1 (en) 2017-10-24 2019-05-02 Genentech, Inc. (4-HYDROXYPYRROLIDIN-2-YL) -HYDROXAMATE COMPOUNDS AND METHODS OF USE
WO2019084026A1 (en) 2017-10-24 2019-05-02 Genentech, Inc. (4-HYDROXYPYRROLIDIN-2-YL) -HETEROCYCLIC COMPOUNDS AND METHODS OF USE
CA3083228A1 (en) 2017-12-14 2019-06-20 Dana-Farber Cancer Institute, Inc. Small molecule degraders that recruit dcaft15
JP2021512059A (ja) 2018-01-29 2021-05-13 ダナ−ファーバー キャンサー インスティテュート,インコーポレイテッド ブルトン型チロシンキナーゼ(btk)阻害剤のe3リガーゼリガンドとのコンジュゲーションによるbtkの分解および使用方法
CA3090275A1 (en) 2018-02-14 2019-08-22 Dana-Farber Cancer Institute, Inc. Irak degraders and uses thereof
WO2019161224A1 (en) 2018-02-15 2019-08-22 GiraFpharma LLC Heterocyclic compounds as kinase inhibitors
WO2019177902A1 (en) 2018-03-10 2019-09-19 Yale University Modulators of btk proteolysis and methods of use
US20200121684A1 (en) 2018-03-10 2020-04-23 Yale University Modulators of btk proteolysis and methods of use
WO2019183523A1 (en) 2018-03-23 2019-09-26 Genentech, Inc. Hetero-bifunctional degrader compounds and their use as modulators of targeted ubiquination (vhl)
CN111936501B (zh) 2018-03-26 2023-09-22 诺华股份有限公司 布鲁顿酪氨酸激酶降解剂
EP3774804A1 (en) 2018-03-26 2021-02-17 Novartis AG N-(3-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl)benzamide derivatives
CN115192726A (zh) 2018-04-03 2022-10-18 深圳大学 免疫激动剂靶向化合物的合成及其应用
WO2019222101A1 (en) 2018-05-14 2019-11-21 Biogen Ma Inc. Inhibiting agents for bruton's tyrosine kinase
WO2020018788A1 (en) 2018-07-20 2020-01-23 Dana-Farber Cancer Institute, Inc. Degraders that target proteins via keap1
CA3108732A1 (en) 2018-08-28 2020-03-05 Merck Patent Gmbh Fused imidazopyridines as reversible inhibitors of bruton's tyrosine kinase (btk)
EP3867242A1 (en) 2018-10-15 2021-08-25 Nurix Therapeutics, Inc. Bifunctional compounds for degrading btk via ubiquitin proteosome pathway
AU2019389174A1 (en) 2018-11-30 2021-07-01 Kymera Therapeutics, Inc. Irak degraders and uses thereof
CN113573782B (zh) 2018-12-21 2025-12-16 Ose免疫疗法公司 针对人pd-1的双功能分子
WO2020127377A1 (en) 2018-12-21 2020-06-25 Ose Immunotherapeutics Bifunctional anti-pd-1/il-7 molecule
US20220056135A1 (en) 2018-12-21 2022-02-24 Ose Immunotherapeutics Bifunctional anti-pd-1/sirpa molecule
EP3924350A1 (en) 2019-02-13 2021-12-22 Nurix Therapeutics, Inc. Bifunctional compounds for degrading btk via ubiquitin proteosome pathway
WO2020165374A1 (en) 2019-02-14 2020-08-20 Ose Immunotherapeutics Bifunctional molecule comprising il-15ra
US12319676B2 (en) 2019-02-15 2025-06-03 Bristol-Myers Squibb Company Substituted amide compounds useful as farnesoid X receptor modulators
WO2020206035A1 (en) 2019-04-01 2020-10-08 G1 Therapeutics, Inc. Treatment of cdk4/6 inhibitor resistant neoplastic disorders
JP7747523B2 (ja) 2019-05-15 2025-10-01 バイオジェン・エムエイ・インコーポレイテッド ブルトン型チロシンキナーゼの阻害剤
WO2020252397A1 (en) 2019-06-12 2020-12-17 Baylor College Of Medicine Small molecule proteolysis-targeting chimeras and methods of use thereof
AU2020301399B2 (en) 2019-06-24 2025-12-18 Dana-Farber Cancer Institute, Inc. HCK degraders and uses thereof
WO2021018018A1 (en) 2019-07-26 2021-02-04 Beigene, Ltd. Degradation of bruton's tyrosine kinase (btk) by conjugation of btk inidbitors with e3 ligase ligand and methods of use
EP4031247A1 (en) 2019-09-16 2022-07-27 Novartis AG Bifunctional degraders and their methods of use
ES3060629T3 (en) 2019-10-30 2026-03-27 Biogen Ma Inc Condensed bi-heterocycles as inhibiting agents for bruton's tyrosine kinase
US12570631B2 (en) 2019-12-23 2026-03-10 Biogen Ma Inc. Substituted N-(4-(pyrimidin and pyridin-4-yl)benzylcarboxamides and its use for treating disorders responsive to inhibition of Btk
TW202140478A (zh) 2020-03-11 2021-11-01 英屬開曼群島商百濟神州有限公司 藉由軛合btk抑制劑與e3連接酶配位基降解布魯頓氏酪胺酸激酶(btk)及其使用方法
EP4146655A4 (en) 2020-04-30 2024-07-31 BeiGene, Ltd. DEGRADATION OF BRUTON TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INHIBITORS WITH E3 LIGASE LIGAND AND METHOD OF USE
UY39370A (es) 2020-08-07 2022-02-25 Biogen Ma Inc Inhibidores de la btk
US20240246977A1 (en) 2020-12-31 2024-07-25 Beigene Switzerland Gmbh Degradation of bruton's tyrosine kinase (btk) by conjugation of btk inhibitors with e3 ligase ligand and method of use
US20240287076A1 (en) 2021-05-05 2024-08-29 Biogen Ma Inc. Compounds for targeting degradation of bruton's tyrosine kinase
AU2022300033A1 (en) 2021-06-21 2024-01-18 Beone Medicines I Gmbh (r) -glutarimide crbn ligands and methods of use
IL309476A (en) 2021-06-30 2024-02-01 Zedira Gmbh Transglutaminase inhibitors
WO2023110138A1 (en) 2021-12-17 2023-06-22 Zedira Gmbh Inhibitors of transglutaminases
DK4192812T3 (da) 2021-06-30 2024-09-16 Zedira Gmbh Transglutaminase-inhibitorer
PL4192813T3 (pl) 2021-06-30 2024-12-23 Zedira Gmbh Inhibitory transglutaminaz
JP2024539269A (ja) 2021-10-22 2024-10-28 グルータクス セラピューティクス (シャンハイ) カンパニー、リミテッド Crbn e3リガーゼリガンド化合物、当該リガンド化合物に基づいて開発したタンパク質分解剤及びそれらの応用
WO2023086521A1 (en) 2021-11-10 2023-05-19 Biogen Ma Inc. Btk inhibitors
AU2022405474B2 (en) 2021-12-08 2026-08-13 Gluetacs Therapeutics (Shanghai) Co., Ltd. E3 ubiquitin ligase ligand compound, protein degrader developed based thereon and their applications
CN118414336A (zh) 2021-12-30 2024-07-30 百济神州有限公司 通过使布鲁顿酪氨酸激酶(btk)抑制剂与e3连接酶配体缀合来降解btk及使用方法
CA3240051A1 (en) 2021-12-30 2023-07-06 Beigene Switzerland Gmbh Degradation of bruton's tyrosine kinase (btk) by conjugation of btk inhibitors with e3 ligase ligand and methods of use

Also Published As

Publication number Publication date
TW202346287A (zh) 2023-12-01
AR128842A1 (es) 2024-06-19
JP2026063166A (ja) 2026-04-10
KR20240163634A (ko) 2024-11-19
CN119072475A (zh) 2024-12-03
EP4249073B1 (en) 2024-12-11
EP4249073A1 (en) 2023-09-27
SI4249073T1 (sl) 2025-02-28
DK4249073T3 (da) 2025-01-02
LT4249073T (lt) 2025-01-27
ES3014292T3 (en) 2025-04-21
EP4480482A2 (en) 2024-12-25
EP4480482A3 (en) 2025-03-26
ZA202504401B (en) 2026-04-29
FI4249073T3 (fi) 2025-02-03
AU2023237882A1 (en) 2024-08-01
JP7805983B2 (ja) 2026-01-26
MX2024011120A (es) 2024-09-18
JP2023140319A (ja) 2023-10-04
US20250304568A1 (en) 2025-10-02
PT4249073T (pt) 2025-01-06
US20240109877A1 (en) 2024-04-04
CO2024012427A2 (es) 2024-09-30
IL314260A (en) 2024-09-01
RS66349B1 (sr) 2025-01-31
WO2023183811A1 (en) 2023-09-28
US12172992B2 (en) 2024-12-24
HUE070665T2 (hu) 2025-06-28
HRP20241722T1 (hr) 2025-02-28

Similar Documents

Publication Publication Date Title
IL314260A (en) Pyrimidines for Broton's tyrosine kinase degradation
IL308219A (en) Compounds to Target Broton Tyrosine Kinase Degradation
PT4139309T (pt) 1,3]diazino[5,4-d]pirimidinas como inibidores de her2
MX2025013699A (es) Una 7-h-pirrolo[2,3-d]pirimidina inhibidora de jak
SG166828A1 (en) Aminopyrimidines useful as kinase inhibitors
AU2009270856A8 (en) Inhibitors of Bruton's tyrosine kinase for the treatment of solid tumors
MXPA04004492A (es) Indazolilpirrolotriazinas c-5 modificadas.
EP2139487A4 (en) BRUTON TYROSINE KINASE HEMMER
ATE508126T1 (de) Als kinaseinhibitoren geeignete aminopyrimidine
ZA200707342B (en) Pyrrolopyrimidines useful as inhibitors of protein kinase
UA99597C2 (ru) Пиримидилциклопентаны как ингибиторы акт протеинкиназ
UA99465C2 (en) Metabolites of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-lh-pyrazol-l-yl)-3- cyclopentylpropanenitrile
MX2009010037A (es) Aminopirimidinas utiles como inhibidores de cinasas.
MX2009011811A (es) Aminopirimidinas utiles como inhibidores de cinasa.
EP3601264A4 (en) BRUTON TYROSINE KINASE INHIBITORS
IL284916A (en) Cyclic molecules as Bruton's tyrosine kinase inhibitors
WO2003032911A3 (en) Anti-angiogenic and cytotoxic fused pyrimidines
CA3252338A1 (en) SYNTHESIS OF BRUTON TYROSINE KINASE INHIBITORS
UA84929C2 (en) Prodrugs of pyrrolylpyrimidine erk protein kinase inhibitors
EP4069689A4 (en) SUBSTITUTED IMIDAZOLECARBOXAMIDE AS BRUTON TYROSINKINASE INHIBITORS
HK40107548A (en) Compounds for targeting degradation of bruton's tyrosine kinase
WO2005009384A3 (en) Egfr tyrosine kinase inhibitors
GB202103176D0 (en) Pyrroloquinoline compounds as modulators of Bruton's tyrosine kinase (BTK).
HK40072430A (en) Dosing of a bruton's tyrosine kinase inhibitor
UA97235C2 (ru) Производные хиназолина и конденсированного пиримидина в качестве ингибитора erbb